Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) (RATIONALE-303)
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
Sponsor: BeiGene
This PHASE3 trial investigates Non-small Cell Lung Cancer and is currently completed. BeiGene leads this study, which shows 25 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
25 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Nov 2024 — Mar 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE3
▶ Show 20 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jun 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2019 — May 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Jul 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jul 2018 [monthly]
Recruiting PHASE3
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BeiGene
For direct contact, visit the study record on ClinicalTrials.gov .